Xxrobxxdo Xxarmxxusaxx Inxx Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxrobxxdo Xxarmxxusaxx Inxx Pharmaceutical Import Records from India — 7 Products, $4.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxrobxxdo Xxarmxxusaxx Inxx — Pharmaceutical Importer Profile (2026) | 7 Products, $4.3M Trade | TransData Nexus

Xxrobxxdo Xxarmxxusaxx Inxx

Pharmaceutical Importer · United States · CNS & Psychiatric Focus · $4.3M Total Trade · DGFT Verified

Xxrobxxdo Xxarmxxusaxx Inxx is a pharmaceutical importer based in United States with a total trade value of $4.3M across 7 products in 4 therapeutic categories. Based on 121 verified import shipments from Indian Customs (DGFT) records, Xxrobxxdo Xxarmxxusaxx Inxx is the #1 buyer in 1 product including Lorazepam. Xxrobxxdo Xxarmxxusaxx Inxx sources from 1 verified Indian supplier, with Apl Healthcare Limited accounting for 100.0% of imports.

Xxrobxxdo Xxarmxxusaxx Inxx — Import Portfolio & Supplier Network

Xxrobxxdo Xxarmxxusaxx Inxx import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxrobxxdo Xxarmxxusaxx Inxx?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Apl Healthcare Limited	$13.5M	367	100.0%

Xxrobxxdo Xxarmxxusaxx Inxx sources from 1 verified Indian supplier across 117 distinct formulations. The sourcing is highly concentrated — Apl Healthcare Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Xxrobxxdo Xxarmxxusaxx Inxx Import?

Formulation	Value	Ships
Potassium chloride extended	$862.8K	20
Losartan potassium tablets 100MG	$765.7K	16
Azelastine hydrochloride	$662.9K	15
Sertraline hydrochloride tablets 100MG	$600.0K	12
Levetiracetam oral solution 100MG/ML	$521.2K	14
Valaciclovir tablets 1000 MG (1g)	$450.0K	9
Ibuprofen oral suspension 100 MG / 5 ML	$409.8K	10
Sevelamer carbonate tablets 800MG	$400.0K	8
Ibuprofen tablets 800 MG	$344.1K	7
Sertraline hydrochloride tablets 50MG	$300.0K	6
Sulfamethoxazole / trimethoprim	$294.5K	16
Losartan potassium tablets 50MG	$244.4K	5
Fluoxetine capsules 40MG	$240.7K	5
Fluoxetine capsules 20MG	$238.8K	5
Gabapentin tablets 800MG	$233.0K	5

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$1.2M	24	0.4%	14
2	Sertraline	CNS & Psychiatric	$1.1M	21	0.2%	10
3	Lorazepam	CNS & Psychiatric	$454.5K	10	18.1%	1
4	Clonazepam	CNS & Psychiatric	$433.6K	22	0.3%	7
5	Sulfamethoxazole	Advanced Antibiotics	$401.2K	17	2.0%	11
6	Trimethoprim	Advanced Antibiotics	$401.2K	17	1.5%	13
7	Prednisone	Respiratory	$383.0K	10	1.4%	15

Xxrobxxdo Xxarmxxusaxx Inxx imports 7 pharmaceutical products across 4 categories into United States totaling $4.3M. The company is the #1 buyer for 1 product: Lorazepam.

Xxrobxxdo Xxarmxxusaxx Inxx — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxrobxxdo Xxarmxxusaxx Inxx is a United States-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. Operating as a buyer, the company plays a pivotal role in sourcing and distributing a diverse range of pharmaceutical products within the U.S. market. Headquartered in the United States, Xxrobxxdo Xxarmxxusaxx Inxx is an independent entity without a publicly known parent company. Its primary function is to procure finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from Indian manufacturers for distribution across the United States. This strategic sourcing approach enables the company to offer a broad spectrum of pharmaceutical products, catering to various therapeutic needs and contributing to the overall efficiency and diversity of the U.S. pharmaceutical supply chain.

2Distribution Network

Xxrobxxdo Xxarmxxusaxx Inxx maintains a robust distribution network within the United States, ensuring efficient delivery of pharmaceutical products to various stakeholders, including wholesalers, pharmacies, and healthcare providers. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of handling a significant volume of shipments. The geographic coverage of Xxrobxxdo Xxarmxxusaxx Inxx spans the entire United States, facilitating nationwide access to its imported pharmaceutical products. This comprehensive distribution network underscores the company's commitment to meeting the diverse needs of the U.S. pharmaceutical market and ensuring timely availability of essential medications.

3Industry Role

In the United States pharmaceutical supply chain, Xxrobxxdo Xxarmxxusaxx Inxx functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Indian manufacturers, the company serves as a critical intermediary between foreign producers and the U.S. market. This role involves ensuring that imported products meet the stringent standards set by U.S. regulatory bodies, including the Food and Drug Administration (FDA). Through its importation and distribution activities, Xxrobxxdo Xxarmxxusaxx Inxx contributes to the diversification and availability of pharmaceutical products in the United States, thereby enhancing the resilience and responsiveness of the domestic pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxrobxxdo Xxarmxxusaxx Inxx

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxrobxxdo Xxarmxxusaxx Inxx exhibits a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier: APL Healthcare Limited. This exclusive sourcing strategy indicates a deep, strategic partnership between the importer and the supplier, potentially leading to favorable terms, consistent product quality, and streamlined logistics. However, such dependency also introduces risks; any disruptions at APL Healthcare Limited—such as production issues, regulatory challenges, or geopolitical events—could significantly impact Xxrobxxdo Xxarmxxusaxx Inxx's ability to meet market demand. The stability of this relationship is crucial, and the company's reliance on a single supplier necessitates robust contingency planning and continuous monitoring of the supplier's operational health to mitigate potential supply chain vulnerabilities.

2Supply Chain Resilience

The resilience of Xxrobxxdo Xxarmxxusaxx Inxx's supply chain is closely tied to the operational stability of APL Healthcare Limited, its sole supplier. Given the absence of publicly available information regarding alternative suppliers or backup sourcing strategies, the company's supply chain appears to be highly concentrated. This lack of diversification may expose Xxrobxxdo Xxarmxxusaxx Inxx to significant risks in the event of disruptions affecting APL Healthcare Limited. To enhance supply chain resilience, it would be prudent for the company to explore potential partnerships with additional suppliers, diversify its product formulations, and develop contingency plans to address unforeseen disruptions. Ensuring compliance with regulatory standards and maintaining open communication channels with suppliers are essential steps in fortifying the supply chain against potential challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug approval, manufacturing practices, labeling, and importation. Pharmaceutical importers must ensure that their products comply with FDA standards for quality, safety, and effectiveness. The FDA's import program involves reviewing shipments to determine their admissibility, with the authority to refuse entry to drugs that are adulterated, misbranded, or unapproved. Additionally, the FDA requires foreign drug establishments to register and list their drugs, ensuring that imported products meet U.S. regulatory standards.

2Import Licensing & GMP

Importers of pharmaceutical products into the United States must adhere to specific licensing and regulatory requirements. Foreign drug establishments that manufacture, repack, re-label, or salvage drug products intended for import into the U.S. are required to register with the FDA and renew their registration annually. These establishments must also list their drugs with the FDA, providing detailed information about each product. Compliance with Good Manufacturing Practice (GMP) standards is mandatory; drugs must be manufactured in facilities that adhere to FDA's GMP regulations to ensure product quality and safety. Importers must verify that their foreign suppliers are registered and that their products are listed with the FDA, ensuring that all imported drugs meet U.S. regulatory standards.

Xxrobxxdo Xxarmxxusaxx Inxx — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxrobxxdo Xxarmxxusaxx Inxx's product strategy focuses on importing pharmaceutical formulations across several therapeutic categories, with a notable emphasis on Central Nervous System (CNS) & Psychiatric, Cardiovascular, and Advanced Antibiotics. The company's top five imported products—Lorazepam, Sertraline, Losartan, Clonazepam, and Sulfamethoxazole—align with these therapeutic areas, indicating a strategic focus on medications that address prevalent health conditions in the United States. The substantial import values and market shares of these products suggest strong demand and a strategic alignment with market needs. By concentrating on these therapeutic categories, Xxrobxxdo Xxarmxxusaxx Inxx aims to meet critical healthcare needs while capitalizing on market opportunities within these segments.

2Sourcing Profile

Xxrobxxdo Xxarmxxusaxx Inxx's sourcing strategy is characterized by a concentrated approach, relying exclusively on APL Healthcare Limited for its pharmaceutical imports. This single-source dependency allows for streamlined operations and potentially favorable terms. However, it also introduces risks associated with supply chain disruptions, regulatory challenges, or operational issues at the supplier's end. The company's focus on finished pharmaceutical formulations from India reflects a strategic decision to leverage India's robust pharmaceutical manufacturing capabilities and cost advantages. To mitigate risks, it would be prudent for Xxrobxxdo Xxarmxxusaxx Inxx to consider diversifying its supplier base and exploring alternative sourcing options.

Frequently Asked Questions — Xxrobxxdo Xxarmxxusaxx Inxx

What products does Xxrobxxdo Xxarmxxusaxx Inxx import from India?

Xxrobxxdo Xxarmxxusaxx Inxx imports 7 pharmaceutical products across 4 categories. Top imports: Losartan ($1.2M), Sertraline ($1.1M), Lorazepam ($454.5K), Clonazepam ($433.6K), Sulfamethoxazole ($401.2K).

Who supplies pharmaceuticals to Xxrobxxdo Xxarmxxusaxx Inxx from India?

Xxrobxxdo Xxarmxxusaxx Inxx sources from 1 verified Indian suppliers. The primary supplier is Apl Healthcare Limited (100.0% of imports, $13.5M).

What is Xxrobxxdo Xxarmxxusaxx Inxx's total pharmaceutical import value?

Xxrobxxdo Xxarmxxusaxx Inxx's total pharmaceutical import value from India is $4.3M, based on 121 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxrobxxdo Xxarmxxusaxx Inxx focus on?

Xxrobxxdo Xxarmxxusaxx Inxx imports across 4 categories. The largest: CNS & Psychiatric (44.8%), Cardiovascular (27.8%), Advanced Antibiotics (18.6%).

Get Full Xxrobxxdo Xxarmxxusaxx Inxx Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Xxrobxxdo Xxarmxxusaxx Inxx

Xxrobxxdo Xxarmxxusaxx Inxx — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Xxrobxxdo Xxarmxxusaxx Inxx?

What Formulations Does Xxrobxxdo Xxarmxxusaxx Inxx Import?

What Products Does Xxrobxxdo Xxarmxxusaxx Inxx Import?

Top Products by Import Value

Xxrobxxdo Xxarmxxusaxx Inxx Therapeutic Categories — 4 Specializations